Rigosertib treatment for skin cancer in patients with a rare genetic condition

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma

This study is testing a new drug called rigosertib to see if it can help people with a rare skin condition and advanced skin cancer when other treatments haven't worked.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Ages: 18 Years to 79 Years
• Sex: All
• Sponsor: Salzburger Landeskliniken (Academic / other)
• Drugs / interventions: cetuximab, panitumumab, nivolumab, pembrolizumab, cemiplimab, chemotherapy, methotrexate
• Locations: 1 site (Salzburg)
• Trial ID: NCT03786237 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the use of rigosertib, an experimental drug, for treating squamous cell carcinoma (SCC) in patients with recessive dystrophic epidermolysis bullosa (RDEB). The trial aims to assess the safety and efficacy of rigosertib in patients who have not responded to standard treatments for advanced SCC. Conducted over approximately 2.5 years, participants will be recruited from two centers in London and Salzburg, with each patient involved for one year. The study focuses on patients with unresectable, locally advanced, or metastatic SCC.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-79 with unresectable, locally advanced or metastatic SCC who have failed standard treatments.

Not a fit: Patients currently receiving other cancer therapies or those without measurable disease will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with RDEB-related SCC, potentially improving survival rates.

How similar studies have performed: While there is limited data on systemic treatments for advanced SCC in RDEB patients, this approach is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

1. 18-79 years of age;
2. Diagnosis of unresectable, locally advanced or metastatic SCC confirmed prior to the Screening Visit.
3. Failure to respond to RDEB SCC standard of care, such as surgical excision, radiotherapy or conventional cytotoxic chemotherapy with e.g. platin derivates (i.e.

   cisplatin or carboplatin), 5-fluorouracil, bleomycin, methotrexate, adriamycin, taxanes, gemcitabine or ifosfamide alone or in combination or failure to respond to previous alternative biologic treatments such as epidermal growth factor inhibitors (like cetuximab and panitumumab) or immune checkpoint (programmed cell death

   1) inhibitors (such as nivolumab, pembrolizumab, cemiplimab). For recent guidelines on standard of care for RDEB SCC and non EB-SCC please see Mellerio et al., 2016; Stratigos et al., 2015 and Kim et al., 2018.
4. Is not currently receiving any other cancer therapy.
5. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
6. Patient (or patient's legally authorized representative) must have signed an informed

Exclusion Criteria

1. Response to standard of care.
2. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris.
3. Active systemic infection not adequately responding to appropriate therapy.
4. Total bilirubin ≥ 1.5 mg/dL (≥5.3 mg/dL in patients if related to hemolysis or Gilbert's disease).
5. Alanine transaminase (ALT)/aspartate transaminase (AST) ≥ 2.5 x upper limit of normal (ULN).
6. Serum creatinine ≥2 .0 mg/dL or eGFR (estimated Glomerular Filtration Rate) \<60mL/min.
7. White blood cell count ≤ 2000/μl, neutrophils ≤ 1500/μL, platelets ≤ 100 x103/μL, hemoglobin ≤ 7.9 g/dL.
8. Known active HIV, hepatitis B or hepatitis C, where active is defined as follows: a. HIV or Hepatitis C - presence of viral load; b. Hepatitis B - antigen positive
9. Uncorrected hyponatremia (defined as serum sodium value of \<125 mmol/L).
10. Male patients with partners of child-bearing potential who are unwilling to use male contraception (condom) throughout the study, up to and including the 30-day nontreatment follow-up period.
11. Female subjects: pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use one or more highly effective and reliable methods of contraception with a Pearl index ≤1 including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral or intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral or injectable or implantable); an intrauterine device (IUD); an intrauterine hormone-releasing system ( IUS); bilateral tubal occlusion; vasectomised partner (provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomised partner has received medical assessment of the surgical success) or sexual abstinence (The reliability of sexuality abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject). Reliable contraception should be maintained throughout the study. A pregnancy test in serum will be performed at screening in all women of childbearing potential, and in urine at all visits. Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) will not be required to undergo pregnancy test.
12. Uncontrolled hypertension. (i.e.. systolic blood pressure greater than or equal to 140mmHg and diastolic blood pressure greater than or equal to 90mmHg despite intake of ≥ 3 antihypertensive medications with complementary mechanisms of action (a diuretic should be 1 component); (Whelton et al., 2018).
13. Patient is currently participating and receiving study therapy or systemic therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
14. Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
15. Patients (or parents in case of paediatric subject) unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments.
16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
17. Known hypersensitivity reaction to any of the components of study treatment.
18. Presence of clinically significant ECG abnormalities based on the inverstigator´s criteria.

Where this trial is running

Salzburg

• EB House Austria/Dept. of Dermatology University Hospital — Salzburg, Austria (Recruiting)

Study contacts

• Principal investigator: Johann W Bauer, Prof., MD — Department of Dermatology, Paracelsus Medical University, Salzburger Landeskliniken
• Study coordinator: Manager EB Study Center

Conditions Epidermolysis Bullosa Dystrophica; Squamous Cell Carcinoma